Clinical Trial

A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination with TT-00420 Tablet in Patients with Advanced Hepatocellular Carcinoma(HCC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-26.
Status change: Not Yet Recruiting → Recruiting 2026-03-13
Trial Details
NCT Number NCT07052253
Lead Sponsor Akeso
Collaborators: TransThera Sciences (Nanjing), Inc.
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 100 participants
Start Date 2025-07-18
Primary Completion 2027-05-10 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-16